ICG 001: Clinical Trials

11 trials of ICG 001, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 recruiting, 1 terminated, 1 withdrawn. 7 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 6, Terminated 1
Phase 25Completed 3, Recruiting 1, Withdrawn 1

Follow ICG 001: new trials by email Literature Review of ICG 001 trials Research Report on ICG 001

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Foscenvivint - Liver Cirrhosis
Phase 2RecruitingKiminori Kimura, MD72026-10-012026-10-05
A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
Foscenvivint - Liver Cirrhosis
Phase 2CompletedKiminori Kimura, MD52024-05-082026-05-01
Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.
OP-724 - Liver Cirrhosis
Phase 1CompletedKiminori Kimura, MD52021-03-152024-10-21
Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)
OP-724 - Primary Biliary Cholangitis (PBC), Liver Cirrhosis, Biliary
Phase 1CompletedKiminori Kimura, MD72019-08-292022-07-07
Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
PRI-724 - Hepatitis C, Hepatitis B
Phase 1 / Phase 2CompletedKiminori Kimura, MD272018-07-242024-10-10
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
CBP/beta-catenin Antagonist PRI-724, Bevacizumab, Leucovorin Calcium - Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer
Phase 2WithdrawnUniversity of Southern California2015-11-012017-04-17
A Follow-up Evaluation Study of PRI-724-1101
PRI-724 - Hepatitis C Virus-infected Cirrhosis
CompletedKomagome Hospital82014-12-182022-07-07
An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis
PRI-724 - Hepatitis C Virus-infected Cirrhosis
Phase 1CompletedKomagome Hospital142014-08-012022-07-07
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
PRI-724 - Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Phase 1CompletedPrism Pharma Co., Ltd.202013-04-012017-08-17
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
PRI-724 - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Phase 1 / Phase 2CompletedPrism Pharma Co., Ltd.492012-07-012017-08-17
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 - Advanced Solid Tumors
Phase 1TerminatedPrism Pharma Co., Ltd.232011-02-012017-08-17

Conditions studied

Liver Cirrhosis (4)  ·  Hemophilia A (3)  ·  Hepatitis C (2)  ·  Pancreatic Neoplasms (2)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Fibrosis (1)  ·  Hepatitis B (1)  ·  Leukemia (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Liver Cirrhosis, Biliary (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)

Sponsors

Kiminori Kimura, MD (5)  ·  Prism Pharma Co., Ltd. (3)  ·  Komagome Hospital (2)  ·  University of Southern California (1)

Countries

Japan (7)  ·  United States (4)

Top investigators

Kiminori Kimura, MD (7)  ·  Anthony El-Khoueiry, MD (1)  ·  Heinz-Josef Lenz (1)  ·  Jorge Cortes, MD (1)  ·  Robert R. McWilliams, M.D. (1)

Results publications

PMID 28844410, PMID 35605429, PMID 36442892, PMID 38677720

NIH funding

P30CA014089 (1), R01CA166161 (1)